CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


ClevudineWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug1231 Intermediate dose thromboprophylaxis Wiki 1.00
drug2325 Standard of Care thromboprophylaxis Wiki 1.00
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D020141 Hemostatic Disorders NIH 0.30
D001778 Blood Coagulation Disorders NIH 0.30

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0001928 Abnormality of coagulation HPO 0.30

There is one clinical trial.

Clinical Trials


1 A Single Blind, Randomized, Placebo-controlled, Multi-center Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients Diagnosed With Moderate COVID-19

The purpose of this clinical trial is to assess the safety and efficacy of Clevudine 120 mg versus placebo once daily administration with standard of care therapy for 14 days (maximum up to 21 days) in patients with moderate COVID-19.

NCT04347915 COVID-19 Drug: Clevudine Drug: Placebo

Primary Outcomes

Description: The primary efficacy endpoint for this clinical trial is the rate of patients with negative SARS-Coronavirus-2 (SARS-CoV-2) in a two-day continuous Real-Time-RT-PCR test from baseline to before the 15th day.

Measure: The rate of subjects tested as negative SARS-Coronavirus-2 (SARS-CoV-2)

Time: within 15days

Secondary Outcomes

Measure: The rate of subjects tested as negative SARS-Coronavirus-2 (SARS-CoV-2) in consecutive two days of Real-Time RT-PCR tests

Time: Day 4, 8, 11, 15, 22, 29(or EOT) day comparing the baseline

Measure: The rate of subjects indicated by the improvement of lung invasive

Time: within Day 29 (or EOT)

Measure: The change of viral load

Time: Day 4, 8, 11, 15, 22, and 29(or EOT) comparing the baseline


No related HPO nodes (Using clinical trials)